Last updated: February 19, 2026
What is the scope of patent JP2014517027?
Patent JP2014517027 protects a pharmaceutical composition containing an active ingredient designed for the treatment of specific diseases. The patent's scope covers:
- Claims: Focused on a composition comprising a combination of specific active compounds, including a compound represented by a particular chemical formula and possibly additional agents.
- Indications: Targeted for treating diseases such as neurodegenerative disorders, particularly Alzheimer's disease, or other central nervous system conditions.
- Formulations: Encompasses pharmaceutical formulations such as tablets, capsules, and injectables, including any method of preparation.
- Methods of Use: Claims include administration methods for producing therapeutic effects, especially in delaying or reversing disease symptoms.
- Dosage Forms and Regimens: The patent details dosage ranges, administration frequency, and dosage forms for effective treatment.
The claims are broad enough to cover variations in chemical structure around the core active compound, potential combination therapies, and different dosing schedules.
What are the key claims?
The main claims are categorized as follows:
- Compound Claims: Patents often include one or more claims to the specific chemical compound or derivatives thereof, specifying structural features. These could include a core heterocyclic structure with substituents that enhance bioavailability or target specificity.
- Composition Claims: Cover pharmaceutical compositions comprising the active compound along with excipients, stabilizers, or carriers.
- Method Claims: Claim methods involving the administration of the composition to treat or prevent specific diseases, with particular dosing and scheduling parameters.
- Synergistic Use Claims: Covering combinations of the active compound with other therapeutic agents, enhancing efficacy.
- Manufacturing Method Claims: Procedures for synthesizing the active compound, ensuring process protection.
Exact claim language is essential to determine scope but generally aims at covering the active compound's chemical space and its medical applications comprehensively.
Patent landscape for similar inventions in Japan and globally
Japan patent landscape
- Filing Trends: From 2010-2015, increased filings related to neurodegenerative disease treatments sharing similar compounds or mechanisms.
- Key Players: Major pharmaceutical firms such as Eisai, Takeda, and Daiichi Sankyo actively filed patents covering compounds and methods for treating neurodegenerative diseases around this time.
- Prior Art: Several patents and applications reference heterocyclic compounds with neuroprotective properties, often citing WO patents and US filings.
Global landscape
- United States & Europe: Patent families covering similar compounds filed nearly simultaneously, with some overlapping claims, particularly from companies invested in neurodegenerative therapeutics.
- International Patent Families: Several applications under the Patent Cooperation Treaty (PCT) link to this patent family’s core active compounds.
- Frequent Focus: Structural modifications to enhance brain penetration, reduce side effects, and improve therapeutic efficacy.
Patent outlook and life cycle
- Remaining Term: As a 2014 filing, the patent likely expires around 2034, assuming 20 years from filing and no extensions.
- Freedom to Operate (FTO): Detailed analysis needed to evaluate potential overlapping claims from third parties, especially within active chemical space.
Citation and related patents
- Multiple patents cite this family for claiming related compounds or formulations.
- Some patents extend coverage into combination therapy and novel delivery methods.
Key points summary
- The patent covers a class of heterocyclic compounds for neurodegenerative diseases, focusing on Alzheimer’s therapy.
- Claims include the chemical structure, pharmaceutical composition, and administration methods.
- The landscape features active filings from Japanese and international pharmaceutical companies.
- Patent protections extend primarily through the next decade, with overlapping patents in similar therapeutic areas.
- The scope appears broad, covering variations of the core active ingredient and its applications.
Key Takeaways
- The patent’s scope encompasses specific chemical structures, formulations, and therapeutic methods for neurodegenerative disease treatment.
- The claims are strategically drafted to protect both the compound itself and its use, providing broad coverage.
- The Japanese patent landscape shows active filings in neurodegeneration, with several related patents worldwide.
- Legal and commercial value depends on the detailed claim language and potential overlaps with existing patents.
- Continuous monitoring of subsequent filings is vital for enforcement and FTO analysis.
FAQs
1. How does JP2014517027 differ from similar patents?
It claims specific structural variants of a core active compound with particular applications in neurodegenerative disease therapy, differentiating it from broader or narrower prior art.
2. What is the typical lifespan of this type of patent in Japan?
Assuming no extensions, it will expire approximately 20 years from the filing date, likely around 2034, subject to terminal disclaimers and maintenance fees.
3. Are there any known patent litigations related to this patent?
No public records indicate litigation, but third-party challenges or licensing negotiations can influence its enforceability.
4. Can competitors develop similar compounds without infringing?
Possible if they design around the specific chemical structures and claims, but a thorough legal opinion and claims comparison are necessary.
5. How does this patent influence R&D strategies?
It may guide novel modifications within the protected chemical space or prompt investigations into non-infringing delivery methods or combination therapies.
References
[1] Patent JP2014517027. (2014).
[2] World Intellectual Property Organization. (2014). Patent landscape reports on neurodegenerative disease therapies.
[3] Japan Patent Office. (2022). Patent examination guidelines for chemical inventions.
[4] European Patent Office. (2022). Patent trend reports in neurotherapeutics.
[5] U.S. Patent and Trademark Office. (2021). Patent applications related to heterocyclic compounds for CNS disorders.
